 A 2007 study reported a sensitivity and specificity of 100% for salivary testosterone in ruling out hypogonadism and concluded that salivary testosterone is a useful biomarker in the diagnosis of male androgen deficiency.The use of salivary testosterone to screen for hypogonadism has been validated by other studies, including one involving 1454 individuals.Those researchers concluded that salivary testosterone is “an acceptable assay for screening for hypogonadism.”

A 2010 study by Zhang, et al., demonstrated that researchers were able to detect pancreatic cancer with high sensitivity and specificity (90.0% and 95.0%, respectively) by screening saliva for four specific mRNA biomarkers.